Boothbay Fund Management’s Abivax ABVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$57.1M Buy
576,871
+13,504
+2% +$1.63M 0.91% 6
2026
Q2
$75.1M Buy
563,367
+90,406
+19% +$10.2M 0.99% 5
2026
Q1
$52.7M Sell
472,961
-34,920
-7% -$4.13M 0.68% 5
2025
Q4
$68.5M Sell
507,881
-90,050
-15% -$9.8M 1.02% 7
2025
Q3
$50.8M Sell
597,931
-272,507
-31% -$16.7M 0.74% 10
2025
Q2
$6.66M Buy
870,438
+299,770
+53% +$1.95M 0.13% 221
2025
Q1
$3.57M Buy
570,668
+163,765
+40% +$1.11M 0.09% 291
2024
Q4
$2.98M Buy
+406,903
New +$3.75M 0.07% 354

Other funds holding ABVX

Boothbay Fund Management's ABVX Position: Q3 2026 in Review

Boothbay Fund Management increased its Abivax (ABVX) stake by 2.4% in Q3 2026, buying an estimated $1.63M and bringing the position to 576,871 shares worth $57.1M. The position accounts for 0.91% of the portfolio, ranked #6.

Boothbay Fund Management first reported a position in ABVX in Q4 2024 and has held it in 8 quarters since. The position peaked at $75.1M in Q2 2026. 305 funds tracked by Wall St. Rank hold ABVX as of Q3 2026.

  • Boothbay Fund Management held 576,871 shares of Abivax worth $57.1M as of Q3 2026.
  • Boothbay Fund Management bought 13,504 Abivax shares in Q3 2026, an estimated $1.63M.
  • Abivax made up 0.91% of Boothbay Fund Management's portfolio in Q3 2026, its #6 holding.
  • Boothbay Fund Management first reported a position in Abivax in Q4 2024 and has held it in 8 quarters since.
  • Boothbay Fund Management's Abivax position peaked at $75.1M in Q2 2026.
  • 305 funds tracked by Wall St. Rank held Abivax as of Q3 2026.

Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.